BeOne Medicines Ltd. (ADR)
General ticker "ONC" information:
- Sector: Health Care
- Industry: Medical - Pharmaceuticals
- Capitalization: $34.8B (TTM average)
BeOne Medicines Ltd. (ADR) follows the US Stock Market performance with the rate: 15.9%.
Estimated limits based on current volatility of 1.5%: low 342.96$, high 353.42$
Factors to consider:
- Total employees count: 12000 (+9.1%) as of 2025
- China accounted for 37.0% of revenue in the fiscal year ended 2024-12-31
- US accounted for 51.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Medicines fail commercial success, Limited commercial experience, Market competition, Limited trading market, Strategic risks and growth management
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [203.54$, 389.07$]
- 2026-12-31 to 2027-12-31 estimated range: [158.65$, 316.52$]
Financial Metrics affecting the ONC estimates:
- Negative: with PPE of 83.1 at the end of fiscal year the price was high
- Positive: 2.37 < Operating cash flow per share per price, % of 3.34
- Positive: 7.80 < Operating profit margin, % of 8.37
- Positive: -16.84 < Industry operating profit margin (median), % of -8.30
- Negative: 49.86 < Shareholder equity ratio, % of 53.26 <= 58.56
- Positive: Inventory ratio change, % of -1.28 <= -0.37
- Positive: Interest expense per share per price, % of 0.17 <= 0.33
- Negative: Investing cash flow per share per price, % of -0.82 <= -0.14
- Negative: Industry earnings per price (median), % of 0 <= 0
Short-term ONC quotes
Long-term ONC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,458.78MM | $3,810.24MM | $5,343.03MM |
| Operating Expenses | $3,666.51MM | $4,378.44MM | $4,895.90MM |
| Operating Income | $-1,207.74MM | $-568.20MM | $447.14MM |
| Non-Operating Income | $381.90MM | $35.20MM | $-30.28MM |
| Interest Expense | $0.00MM | $0.00MM | $58.23MM |
| R&D Expense | $1,778.59MM | $1,953.30MM | $2,145.87MM |
| Income(Loss) | $-825.84MM | $-533.00MM | $416.85MM |
| Taxes | $55.87MM | $111.78MM | $129.92MM |
| Net Income(Loss)* | $-881.71MM | $-644.79MM | $286.93MM |
| Stockholders Equity | $3,537.33MM | $3,332.22MM | $4,361.19MM |
| Inventory | $416.12MM | $494.99MM | $608.23MM |
| Assets | $5,805.27MM | $5,920.91MM | $8,188.57MM |
| Operating Cash Flow | $-1,157.45MM | $-140.63MM | $1,127.58MM |
| Capital expenditure | $596.26MM | $529.14MM | $185.84MM |
| Investing Cash Flow | $60.00MM | $-548.35MM | $-276.15MM |
| Financing Cash Flow | $416.48MM | $193.45MM | $1,059.45MM |
| Earnings Per Share** | $-8.45 | $-6.12 | $2.63 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.